<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628858</url>
  </required_header>
  <id_info>
    <org_study_id>H-19086583</org_study_id>
    <nct_id>NCT04628858</nct_id>
  </id_info>
  <brief_title>Wireless Assessment of Respiratory and Circulatory Distress in Vascular Surgical Patients - An Observational Study</brief_title>
  <acronym>WARD-VASC</acronym>
  <official_title>Continuous Monitoring of Physiological Parameters for Early Detection of Complications in Postoperative Vascular Surgical Patients - An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eske Kvanner Aasvang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular postsurgical patients have a high risk of morbidity and mortality. On top of that,&#xD;
      patients undergoing vascular surgery usually have a high burden of comorbidities.&#xD;
&#xD;
      After a short stay in the post-operative ward, patients are usually transferred to a standard&#xD;
      surgical ward.&#xD;
&#xD;
      Monitoring of physiological parameters by intermittent manual recordings 8-12 hours apart, is&#xD;
      today's standard of care in hospitals. However, no effect on length of hospital stay,&#xD;
      morbidity or mortality has been proven. This may be due to the up to 12 hours of unobserved&#xD;
      time that can occur, where physiological deviations can progress resulting in clinical&#xD;
      adverse outcomes such as myocardial infarction or stroke.&#xD;
&#xD;
      Vital sign micro events are occurrences when patient physiological parameters deviates&#xD;
      significantly from what can be understood as normal physiology. Since adverse outcomes in&#xD;
      patients rarely happens without deviating physiological parameters, it is to be investigated&#xD;
      if micro events can be used to predict clinical adverse outcomes to patients. We acknowledge&#xD;
      that during the observation period, the number of false alarms should be kept to a minimum to&#xD;
      avoid the risk of 'alarm fatigue'&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">July 23, 2021</completion_date>
  <primary_completion_date type="Actual">January 23, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Physiologic abnormal vital signs</measure>
    <time_frame>From inclusion until 4 days or discharge</time_frame>
    <description>Duration of physiologic abnormal vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Will be defined in protocol appendix A.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Complication of Surgical Procedure</condition>
  <condition>Complication of Anesthesia</condition>
  <condition>Respiratory Complication</condition>
  <condition>Circulatory; Complications</condition>
  <arm_group>
    <arm_group_label>Primary group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Troponin-T&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        40 patients admitted for elective or subacute vascular surgical intervention, as noted in&#xD;
        the inclusion criteria, will be included on the day before their surgical procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to Copenhagen University Hospital&#xD;
&#xD;
          -  Patients with Peripheral Arteriel Disease(PAD)&#xD;
&#xD;
          -  Patients undergoing open infraligamentary revascularization&#xD;
&#xD;
          -  Emergency or subacute surgery&#xD;
&#xD;
          -  Admission the day before surgery, and expected length of stay more than 2 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient expected not to cooperate&#xD;
&#xD;
          -  Patients with dementia or not able to give informed consent&#xD;
&#xD;
          -  Patient allergic to plaster, plastic or silicone&#xD;
&#xD;
          -  Patients with pacemaker or implantable cardioverter-defibrillator (ICD) unit&#xD;
&#xD;
          -  Patients in isolation&#xD;
&#xD;
          -  Active therapy withdrawn&#xD;
&#xD;
          -  Patients previously included in the other study branches&#xD;
&#xD;
          -  Patients with &gt;20 mmHg in difference in systolic blood pressure between the two arms.&#xD;
&#xD;
          -  Expected discharge within less than 24 hours from possible inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eske K Aasvang</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Eske Kvanner Aasvang</investigator_full_name>
    <investigator_title>Dr. Med.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

